
In a pooled analysis from the BOREAS and NOTUS trials, dupilumab significantly reduced the annualised rate of moderate or severe COPD exacerbations compared to placebo (0.794 vs 1.156, p<0.0001). Additionally, dupilumab delayed the time to first severe exacerbation.
Like
Save
Share